Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nano HoldingsTSE:4571 +1.02%43 3-Year EBITDA Growth Rate is 11.00% as of Mar. 2026, which is 19% above its 10-year median of 9.25. GuruFocus rates TSE:4571 with a GF Score™ of 43/100 and a GF Value™ of 円185.64 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,124 Biotechnology companies, Nano Holdings ranks worse than 54.98% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nano Holdings was 46.30% per year. The lowest was -66.00% per year. And the median was 9.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nano Holdings 3-Year EBITDA Growth Rate Related Terms
TSE:4571 vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Nano Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nano Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nano Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nano Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.00% mean?
Nano Holdings (TSE:4571) has a 3-Year EBITDA Growth Rate of 11.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nano Holdings and its competitors. This is 19% above median its historical median of 9.25. According to the industry distribution chart, Nano Holdings ranks #618 out of 1124 companies in the Biotechnology industry, placing it in the top 55%.
Is Nano Holdings' 3-Year EBITDA Growth Rate too high?
Nano Holdings' current 3-Year EBITDA Growth Rate of 11.00% is 19% above median its 10-year median of 9.25. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Nano Holdings' value of 11.00% is 24.9% below this industry median. Based on the distribution chart, Nano Holdings ranks #618 out of 1124 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nano Holdings has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nano Holdings' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nano Holdings ranks #618 out of 1124 companies for 3-Year EBITDA Growth Rate. This places Nano Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Nano Holdings' value of 11.00% is 24.9% below this benchmark. While the company's 10-year median is 9.25 vs. the industry median of 14.65, Nano Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nano Holdings's current 3-Year EBITDA Growth Rate of 11.00% is 24.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nano Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nano Holdings's current 3-Year EBITDA Growth Rate is 11.00%, which is 19% above median its own 10-year median of 9.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nano Holdings stock overvalued right now?
Based on GuruFocus' analysis, Nano Holdings (TSE:4571) is currently considered Possible Value Trap. The stock's GF Value™ is 円185.64, compared to a current price of 円99.00 — trading 46.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.00%, which is 19% above median its 10-year median of 9.25 and 24.9% below the Biotechnology industry median of 14.65. Nano Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nano Holdings (TSE:4571), the current 3-Year EBITDA Growth Rate is 11.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nano Holdings (TSE:4571) Overvalued in 2026?
Based on GuruFocus' analysis, Nano Holdings stock appears to be undervalued.
The current stock price of 円99.00 is trading 46.7% below its estimated GF Value™ of 円185.64.
GuruFocus considers Nano Holdings to be Possible Value Trap.
Key valuation signals for TSE:4571:
3-Year EBITDA Growth Rate: 11.00% (19% above median its 10-year median of 9.25)
GF Value™: 円185.64 vs. price of 円99.00 (46.7% below fair value)
Industry Position: 24.9% below the Biotechnology median (#618 of 1124)
No single metric tells the full story. See the TSE:4571 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nano Holdings Inc formerly, Nano Mrna Co Ltd is engaged in the research and development of pharmaceuticals using micellar nanoparticle technology. The Group's business is a single segment that involves research and development, manufacturing, and sales of pharmaceuticals and other products, as well as related operations.
43GF Score
Get the complete analysis for TSE:4571
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4571 has been successfully added to your 
